Physiomics Share Discussion Threads

[chicken charlie] 20/8/2020 14:56

8p this afternoon

[albert3591] 20/8/2020 14:52

Afternoon all ready for a drop,I’ll see what I can do.

[the stigologist] 20/8/2020 13:45

All the good investors seem to be adding today.

I have added substantially in the 7s despite having an average in the 3s

My minimum target is parity on a Mkt Cap/Revenue basis with Simulations Plus which is trading on over 30x revenue

The 100p manifesto makes the case for why PYC should trade at a PREMIUM to Simulations Plus on account of

1. PYC is a smaller specialist in a field Simulations Plus have no product and thus an acquisition target worthy of an additional 'takeover premium' in its rating

2. PYC is growing revenues at 70% versus Sim Plus growing at only c.15%

[hodhasharon] 20/8/2020 13:04

For anyone looking to have a dabble here....read the 100p Manifesto which was published a couple of weeks ago. It's a fact-based conservative prediction supporting a 100p valuation of PYC.

[tonytony4] 20/8/2020 13:00

Hopefully seller is done so Adding as and when this should start to head nearer 10p imo..

[hodhasharon] 20/8/2020 12:57

Great investment.

[chicken charlie] 20/8/2020 12:56

I've added again today too Hod

[spudyoulike] 20/8/2020 12:55

I've added again today too Hod

[hodhasharon] 20/8/2020 12:36

forgot to mention. 25k added into SIPP this morning.

[hodhasharon] 20/8/2020 12:30

Our route to the 100p Manifesto target looks to be making good progress.

Should see a steady rise to 17p now.

[spudyoulike] 20/8/2020 11:57

Dave, your reply was so predictable LMAO. I don't blame you for trying to drag back an inch of credibility. I made a mistake... I made the assumption that VAL were already in trial 3. This was based partly from some investors messages + the time that has already lapsed but the blame is on me and me only. As soon as I read the VAL RNS I owned my mistake knowing full well that you would try and run with it. I am a man in that regard. You on the other hand said that "it never happened " what ever that was supposed to mean. And I knew full well that it had and hence why I refuted your argument. You then went on to say that they had been in pre-clinical trials for ten years and not yet started clinical trials. Load of rubbish. You bare face lie and think that's ok. Good for you Dave.

[the stigologist] 20/8/2020 11:03

ANY licensing income

www.proactiveinvestors.co.uk/companies/news/27661/ValiRx-teams-up-with-Physiomics-to-accelerate-the-development-of-anti-cancer-compound-33038.html

[the stigologist] 20/8/2020 11:02

TRANSFORMATIONAL

[the stigologist] 20/8/2020 10:30

Someone is not getting any 🤣

[spudyoulike] 19/8/2020 22:04

I concur that Only clinical trails l&ll have closed but the point still stands. The argument was based on the fact that PYC has rights to profit share on VAL201 (not clinical/pre-clinical timeliness) and they clearly do. And it is important because 'if' the trials are a big success then PYC stands to benefit considerably and I don't blame investors for getting excited for that possibility. They have their rights to ramp as you have yours to de-ramp.

[spudyoulike] 19/8/2020 21:25

"And of course 5 years isn't nonsense, it's taken nearly ten to get through pre clinical." You've exposed yourself as a complete fraud. End of talks with you.

[spudyoulike] 19/8/2020 21:24

Val RNS from today. VAL201The Phase 1/2 clinical trial of VAL201 in the treatment of men with prostate cancer was closed to further recruitment on 27 January 2020, with recruitment standing at a total of 12 patients dosed across 5 cohorts. The dose escalation was carried out from 0.5 mg/kg up to 8 mg/kg with dosing being carried out once a week.The trial considered the safety and tolerability of drug administration, alongside pharmacokinetics and disease impact. Although the COVID-19 pandemic lockdown initially cast concern on the time schedules for data verification processes, the project remains on track to release headline results within Q3 2020, which will provide basic details of safety, tolerability and disease impact. More detailed observations on the pharmacokinetics and complete summaries of patient demographics, biochemistry and study conduct will be available when the Clinical Study Report is completed in Q4 2020.

[spudyoulike] 19/8/2020 21:15

It's rather telling that you had to read up on clinical trials Dave. I can smell your ignorance from here.

[spudyoulike] 19/8/2020 21:12

They was pre-clinical when PYC was working with them to get the drug ready for clinical.

[spudyoulike] 19/8/2020 21:11

I was reading a company RNS or article yesterday where FDA approval was rushed through. I will find and post for you.